Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 8, 2010

University of Cardiff Spin-Out to Develop Cell-Based Cartilage-Replacement Therapy

  • Progenteq has been spun out from Cardiff University to develop a cell-based cartilage-replacement therapy. The company has been set up by Fusion IP, a university commercialization company that has exclusive rights to 100% of university-owned research generated at Cardiff University and the The University of Sheffield.

    The cartilage-replacement technology exploits a defined population of articular cartilage cells that Fusion claims display stem cell like properties and can be expanded ex vivo to generate large quantities of cartilage. Progenteq hopes to develop these cells as a stored bank of material for allogeneic cartilage-replacement therapy in patients with acute injuries.

    The company suggests that allogeneic implants would be more cost-effective than autologous approaches requiring the expansion of cartilage cells derived from individual patients. It also believes a cartilage cell bank could pave the way for new treatments against degenerative disorders such as osteoarthritis.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »